Paradigm Biopharmaceuticals Ltd. has released a press release.
Agreement to Return US$2M to Obsidian
Earlier from Paradigm Biopharmaceuticals
- Phase 3 Interim Result Below Continuation Threshold
- Suspension from Quotation
- Appendix 4E and 2026 Annual Report
- June 2026 Quarterly Activities Report & Appendix 4C